Company Overview
STAAR Surgical Company is dedicated to the design, development, manufacturing, and sale of phakic implantable lenses for the eye, along with the accessory delivery systems required to implant these lenses. This specialized focus places the firm squarely within the Healthcare sector, specifically operating in the Medical Instruments & Supplies industry, where innovation in ophthalmic technology is critical for patient outcomes. The company's operational scale is defined by a market capitalization of $900.14M, annual revenue of $239.44M, and an employment base of 921 individuals. These financial metrics indicate a mid-sized enterprise that commands a significant portion of the niche market for implantable collamer lens products while maintaining a substantial workforce to support its R&D and distribution capabilities.
Financial Health
The company reported a revenue of $239.44M over the trailing twelve months, yet posted a net income of $-80,448,000 and an EBITDA of $-37,419,000, revealing a substantial gap between top-line generation and bottom-line profitability that points to significant operational costs or non-operating expenses impacting the bottom line. Despite the negative net income and EBITDA, the firm generated positive free cash flow of $14.61M, which suggests that the business maintains sufficient operational cash generation to fund activities without immediate external financing, providing a degree of financial flexibility. Profitability analysis shows a gross margin of 76.2%, indicating strong pricing power or low cost of goods sold, while the operating margin stands at -18.9% and the profit margin is -33.6%, signaling that high fixed costs or other expenses are eroding operating income significantly. The balance sheet presents a conservative profile with cash reserves of $187.54M against total debt of $38.35M, supported by a low debt-to-equity ratio of 11.14%. Liquidity is robust, evidenced by a current ratio of 4.55, which indicates the company holds more than four times the current assets necessary to cover its short-term liabilities. However, return metrics reflect the current lack of profitability, with a return on equity of -21.7% and a return on assets of -5.9%, revealing that management is currently generating negative returns on the capital invested in the business.
Valuation Assessment
Valuation metrics present a complex picture, with a trailing P/E ratio listed as N/A due to the net loss, while the forward P/E is calculated at 22.12, implying that the market anticipates a significant earnings turnaround in the future to justify this multiple. The price-to-book ratio sits at 2.61, indicating that the market values the company at a premium of 161% over its net book value, likely reflecting the intangible value of its intellectual property and market position. Alternative valuation measures such as the price-to-sales ratio of 3.76 and an EV/EBITDA of -19.20 suggest the stock is priced based on revenue multiples rather than current earnings, as the negative EV/EBITDA confirms the company is not yet profitable on an earnings basis. Regarding price momentum, the stock has a 52-week high of $30.81 and a 52-week low of $14.69, meaning the current trading price is positioned within the volatility range established by recent market activity. The beta value of 1.05 indicates that the stock's price volatility is slightly higher than the broader market, moving in tandem with general market fluctuations but with a marginally increased sensitivity to market swings.
Growth & Income
Revenue growth for the trailing twelve months stands at 18.1%, demonstrating a strong expansion in sales volume or pricing, whereas earnings growth is listed as N/A due to the recent net loss, implying that top-line growth has not yet translated into bottom-line improvements. The company does not pay a dividend, as indicated by a dividend yield of N/A and a payout ratio of 0.0%, which means the firm retains all its earnings to fund growth initiatives, research, and debt reduction rather than distributing income to shareholders. This reinvestment strategy is typical for growth-stage medical device companies that prioritize expanding their product portfolio and market share over returning capital to investors. The overall growth and income profile for STAAR Surgical Company is characterized by robust revenue expansion and a complete absence of dividend payments, reflecting a capital allocation strategy focused on long-term operational scaling rather than immediate income generation.